The newly formed RxCapital has made its first investment, in metabolic and cardiovascular disease drug developer Rivus Pharmaceuticals' $35m series A round.
RxCelerate, a UK-based contract research organisation (CRO) for drug discovery and development, has set up a corporate venture capital fund called RxCapital. The vehicle will invest up to £1m ($1.2m) in each company it backs and is targeting developers of therapeutics for unmet medical needs. Investments come with no requirement for the company to use RxCelerate’s…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.